@article{czochra,
  title={Modeling of asymmetric cell division in hematopoietic stem cells—regulation of self-renewal is essential for efficient repopulation},
  author={Marciniak-Czochra, Anna and Stiehl, Thomas and Ho, Anthony D and J{\"a}ger, Willi and Wagner, Wolfgang},
  journal={Stem cells and development},
  volume={18},
  number={3},
  pages={377--386},
  year={2009},
  publisher={Mary Ann Liebert, Inc. publishers 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801-5215 USA}
}

@article{sottoriva,
  title={The cancer stem cell fraction in hierarchically organized tumors can be estimated using mathematical modeling and patient-specific treatment trajectories},
  author={Werner, Benjamin and Scott, Jacob G and Sottoriva, Andrea and Anderson, Alexander RA and Traulsen, Arne and Altrock, Philipp M},
  journal={Cancer research},
  volume={76},
  number={7},
  pages={1705--1713},
  year={2016},
  publisher={AACR}
}
@article{stiehl2018mathematical,
  title={Mathematical modeling of the impact of cytokine response of acute myeloid leukemia cells on patient prognosis},
  author={Stiehl, Thomas and Ho, Anthony D and Marciniak-Czochra, Anna},
  journal={Scientific reports},
  volume={8},
  number={1},
  pages={2809},
  year={2018},
  publisher={Nature Publishing Group}
}



@article{michor2005,
  title={Dynamics of chronic myeloid leukaemia},
  author={Michor, Franziska and Hughes, Timothy P and Iwasa, Yoh and Branford, Susan and Shah, Neil P and Sawyers, Charles L and Nowak, Martin A},
  journal={Nature},
  volume={435},
  number={7046},
  pages={1267},
  year={2005},
  publisher={Nature Publishing Group}
}

@article{tang2011dynamics,
  title={Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells},
  author={Tang, Min and Gonen, Mithat and Quintas-Cardama, Alfonso and Cortes, Jorge and Kantarjian, Hagop and Field, Chani and Hughes, Timothy P and Branford, Susan and Michor, Franziska},
  journal={Blood},
  volume={118},
  number={6},
  pages={1622-1631},
  year={2011},
  publisher={Am Soc Hematology}
}
@article{holyoake2017chronic,
  title={The chronic myeloid leukemia stem cell: stemming the tide of persistence},
  author={Holyoake, Tessa L and Vetrie, David},
  journal={Blood},
  volume={129},
  number={12},
  pages={1595--1606},
  year={2017},
  publisher={Am Soc Hematology}
}

@article{kumari2012low,
  title={Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib},
  author={Kumari, Ashu and Brendel, Cornelia and Hochhaus, Andreas and Neubauer, Andreas and Burchert, Andreas},
  journal={Blood},
  volume={119},
  number={2},
  pages={530--539},
  year={2012},
  publisher={Am Soc Hematology}
}

@article{hughes2016treatment,
  title={Treatment-free remission in patients with chronic myeloid leukemia in chronic phase according to reasons for switching from imatinib to nilotinib: subgroup analysis from ENESTop},
  author={Hughes, Timothy P and Boquimpani, Carla Maria and Takahashi, Naoto and Benyamini, Noam and Clementino, Nelma Cristina D and Shuvaev, Vasily and Ailawadhi, Sikander and Lipton, Jeffrey H and Turkina, Anna G and Moiraghi, Elena Beatriz and others},
  year={2016},
  publisher={Am Soc Hematology}
}


@article{branford2013early,
  title={Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML},
  author={Branford, Susan and Yeung, David T and Ross, David M and Prime, Jodi A and Field, Chani R and Altamura, Haley K and Yeoman, Alexandra L and Georgievski, Jasmina and Jamison, Bronte A and Phillis, Stuart and others},
  journal={Blood},
  volume={121},
  number={19},
  pages={3818--3824},
  year={2013},
  publisher={Am Soc Hematology}
}
@article{moore2004mathematical,
  title={A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction},
  author={Moore, Helen and Li, Natasha K},
  journal={Journal of theoretical biology},
  volume={227},
  number={4},
  pages={513--523},
  year={2004},
  publisher={Elsevier}
}


@article{experts2013price,
  title={The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts},
  author={Experts in Chronic Myeloid Leukemia and others},
  journal={Blood},
  volume={121},
  number={22},
  pages={4439--4442},
  year={2013},
  publisher={Am Soc Hematology}
}

@article{gomez2017insights,
  title={Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective},
  author={Gomez-de-Le{\'o}n, Andr{\'e}s and G{\'o}mez-Almaguer, David and Ruiz-Delgado, Guillermo J and Ruiz-Arguelles, Guillermo J},
  journal={Expert review of hematology},
  volume={10},
  number={9},
  pages={809--819},
  year={2017},
  publisher={Taylor \& Francis}
}

 @article{jabbour,
  title={Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase},
  author={Jabbour, Elias J and Lin, Jay and Siegartel, Lisa R and Lingohr-Smith, Melissa and Menges, Brandy and Makenbaeva, Dinara},
  journal={Journal of medical economics},
  volume={20},
  number={9},
  pages={1007--1012},
  year={2017},
  publisher={Taylor \& Francis}
}

@article{faber2016lower,
  title={A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment},
  author={Faber, Edgar and Divok{\'a}, Martina and Skoumalov{\'a}, Ivana and Nov{\'a}k, Martin and Mare{\v{s}}ov{\'a}, Ivana and Mi{\v{c}}ov{\'a}, Kate{\v{r}}ina and Friedeck{\`y}, David and Adam, Tom{\'a}{\v{s}} and Jaro{\v{s}}ov{\'a}, Marie and Indr{\'a}k, Karel},
  journal={Leukemia \& lymphoma},
  volume={57},
  number={2},
  pages={370--375},
  year={2016},
  publisher={Taylor \& Francis}
}

@article{hughes2014safety,
  title={Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily},
  author={Hughes, Timothy P and Hochhaus, Andreas and Kantarjian, Hagop M and Cervantes, Francisco and Guilhot, Fran{\c{c}}ois and Niederwieser, Dietger and le Coutre, Philipp D and Rosti, Gianantonio and Ossenkoppele, Gert and Lobo, Clarisse and others},
  journal={haematologica},
  volume={99},
  number={7},
  pages={1204--1211},
  year={2014},
  publisher={Haematologica}
}
@article{quintas2009dynamics,
  title={Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure},
  author={Quint{\'a}s-Cardama, Alfonso and De Souza Santos, Fabio Pires and Kantarjian, Hagop and O'brien, Susan and Faderl, Stefan and Awais, Ahmed and Borthakur, Gautam and Cortes, Jorge},
  journal={Cancer},
  volume={115},
  number={17},
  pages={3935--3943},
  year={2009},
  publisher={Wiley Online Library}
}

@article{cumbo2018genomic,
  title={Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for “personalized monitoring” of residual disease in chronic myeloid leukemia patients},
  author={Cumbo, Cosimo and Impera, Luciana and Minervini, Crescenzio Francesco and Orsini, Paola and Anelli, Luisa and Zagaria, Antonella and Coccaro, Nicoletta and Tota, Giuseppina and Minervini, Angela and Casieri, Paola and others},
  journal={Oncotarget},
  volume={9},
  number={13},
  pages={10978},
  year={2018},
  publisher={Impact Journals, LLC}
}


@article{talpaz2018dasatinib,
  title={Dasatinib dose management for the treatment of chronic myeloid leukemia},
  author={Talpaz, Moshe and Saglio, Giuseppe and Atallah, Ehab and Rousselot, Philippe},
  journal={Cancer},
  year={2018},
  publisher={Wiley Online Library}
}


@article{atallah2018design,
  title={Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia},
  author={Atallah, Ehab and Schiffer, Charles A and Weinfurt, Kevin P and Zhang, Mei-Jie and Radich, Jerald P and Oehler, Vivian G and Pinilla-Ibarz, Javier and Deininger, Michael WN and Lin, Li and Larson, Richard A and others},
  journal={BMC cancer},
  volume={18},
  number={1},
  pages={359},
  year={2018},
  publisher={BioMed Central}
}

@article{cortes2016evaluating,
  title={Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study},
  author={Cortes, Jorge E and Lipton, Jeffrey H and Miller, Carole B and Busque, Lambert and Akard, Luke P and Pinilla-Ibarz, Javier and Keir, Christopher and Warsi, Ghulam and Lin, Felice P and Mauro, Michael J},
  journal={Clinical Lymphoma, Myeloma and Leukemia},
  volume={16},
  number={5},
  pages={286--296},
  year={2016},
  publisher={Elsevier}
}


@article{baccarani2012chronic,
  title={Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up},
  author={Baccarani, M and Pileri, S and Steegmann, J-L and Muller, M and Soverini, S and Dreyling, M and ESMO Guidelines Working Group},
  journal={Annals of oncology},
  volume={23},
  number={suppl\_7},
  pages={vii72--vii77},
  year={2012},
  publisher={Oxford University Press}
}
@article{baccarani2009chronic,
  title={Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet},
  author={Baccarani, Michele and Cortes, Jorge and Pane, Fabrizio and Niederwieser, Dietger and Saglio, Giuseppe and Apperley, Jane and Cervantes, Francisco and Deininger, Michael and Gratwohl, Alois and Guilhot, Fran{\c{c}}ois and others},
  journal={Journal of clinical oncology},
  volume={27},
  number={35},
  pages={6041},
  year={2009},
  publisher={American Society of Clinical Oncology}
}

@article{assouline2011monitoring,
  title={Monitoring response and resistance to treatment in chronic myeloid leukemia},
  author={Assouline, Sarit and Lipton, Jeffrey H},
  journal={Current Oncology},
  volume={18},
  number={2},
  pages={e71},
  year={2011},
  publisher={Multimed Inc.}
}


@article{bhamidipati2013management,
  title={Management of imatinib-resistant patients with chronic myeloid leukemia},
  author={Bhamidipati, Pavan Kumar and Kantarjian, Hagop and Cortes, Jorge and Cornelison, A Megan and Jabbour, Elias},
  journal={Therapeutic advances in hematology},
  volume={4},
  number={2},
  pages={103--117},
  year={2013},
  publisher={SAGE Publications Sage UK: London, England}
}

@article{nanda2007optimal,
  title={Optimal control of treatment in a mathematical model of chronic myelogenous leukemia},
  author={Nanda, Seema and Moore, Helen and Lenhart, Suzanne},
  journal={Mathematical biosciences},
  volume={210},
  number={1},
  pages={143--156},
  year={2007},
  publisher={Elsevier}
}
@article{mughal2006molecularly,
  title={Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era},
  author={Mughal, Tariq I and Goldman, John M},
  journal={Front Biosci},
  volume={11},
  pages={209--220},
  year={2006}
}





@article{massimino2018non,
  title={Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia},
  author={Massimino, Michele and Stella, Stefania and Tirr{\`o}, Elena and Romano, Chiara and Pennisi, Maria Stella and Puma, Adriana and Manzella, Livia and Zangh{\`\i}, Antonino and Stagno, Fabio and Di Raimondo, Francesco and others},
  journal={Molecular cancer},
  volume={17},
  number={1},
  pages={56},
  year={2018},
  publisher={BioMed Central}
}

@article{olshen2014dynamics,
  title={Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib},
  author={Olshen, Adam and Tang, Min and Cortes, Jorge and Gonen, Mithat and Hughes, Timothy and Branford, Susan and Quint{\'a}s-Cardama, Alfonso and Michor, Franziska},
  journal={haematologica},
  pages={haematol--2013},
  year={2014},
  publisher={Haematologica}
}

@article{mahon2010discontinuation,
  title={Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial},
  author={Mahon, Fran{\c{c}}ois-Xavier and R{\'e}a, Delphine and Guilhot, Jo{\"e}lle and Guilhot, Fran{\c{c}}ois and Huguet, Fran{\c{c}}oise and Nicolini, Franck and Legros, Laurence and Charbonnier, Aude and Guerci, Agn{\`e}s and Varet, Bruno and others},
  journal={The lancet oncology},
  volume={11},
  number={11},
  pages={1029--1035},
  year={2010},
  publisher={Elsevier}
}


@article{tannenbaum2018control,
  title={Control and the Analysis of Cancer Growth Models},
  author={Tannenbaum, Allen R and Georgiou, Tryphon and Deasy, Joseph and Norton, Larry},
  journal={bioRxiv},
  pages={244301},
  year={2018},
  publisher={Cold Spring Harbor Laboratory}
}

@article{rainero2018gdna,
  title={gDNA qPCR is statistically more reliable than mRNA analysis in detecting leukemic cells to monitor CML},
  author={Rainero, Alessia and Angaroni, Fabrizio and Conti, Andrea and Pirrone, Cristina and Micheloni, Giovanni and Tarar{\`a}, Lucia and Millefanti, Giorgia and Maserati, Emanuela and Valli, Roberto and Spinelli, Orietta and others},
  journal={Cell death \& disease},
  volume={9},
  number={3},
  pages={349},
  year={2018},
  publisher={Nature Publishing Group}
}



@article{ishida2016pharmacokinetics,
  title={Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia},
  author={Ishida, Yoji and Murai, Kazunori and Yamaguchi, Kohei and Miyagishima, Takuto and Shindo, Motohiro and Ogawa, Kazuei and Nagashima, Takahiro and Sato, Shinji and Watanabe, Reiko and Yamamoto, Satoshi and others},
  journal={European journal of clinical pharmacology},
  volume={72},
  number={2},
  pages={185--193},
  year={2016},
  publisher={Springer}
}
@article{altrock2015mathematics,
  title={The mathematics of cancer: integrating quantitative models},
  author={Altrock, Philipp M and Liu, Lin L and Michor, Franziska},
  journal={Nature Reviews Cancer},
  volume={15},
  number={12},
  pages={730},
  year={2015},
  publisher={Nature Publishing Group}
}

@book{chapman-book,
  title={Optimal control applied to biological models},
  author={Lenhart, Suzanne and Workman, John T},
  year={2007},
  publisher={Crc Press}
}



@article{experiment-affidabile-1,
  title={Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-$\alpha$ therapy},
  author={Tchirkov, Andrei and Giollant, Michel and Tavernier, Fran{\c{C}}oise and Brian{\c{C}}on, Georges and Tournilhac, Olivier and Kwiatkowski, Fabrice and Philippe, Pierre and Choufi, Bachra and Dem{\'E}ocq, Fran{\c{C}}ois and Travade, Philippe and others},
  journal={British journal of haematology},
  volume={101},
  number={3},
  pages={552--557},
  year={1998},
  publisher={Wiley Online Library}
}


@article{experiment-affidabile-2,
  title={Correlation between BCR-ABL expression and tumor burden is restricted to the transition from minor to major cytogenetic response in interferon treated CML patients},
  author={Kereskai, L{\'a}szl{\'o} and Vass, J{\'a}nos A and Kneif, Maria and Pajor, L{\'a}szl{\'o}},
  journal={Pathology Oncology Research},
  volume={9},
  number={3},
  pages={174--179},
  year={2003},
  publisher={Springer}
}
@article{experiment-affidabile-3,
  title={Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.},
  author={Lion, T and Gaiger, A and Henn, T and H{\"o}rth, E and Haas, OA and Geissler, K and Gadner, H},
  journal={Leukemia},
  volume={9},
  number={8},
  pages={1353--1360},
  year={1995}
}
@article{experiment-affidabile-4,
  title={Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.},
  author={Hochhaus, A and Lin, F and Reiter, A and Skladny, H and Mason, PJ and Shepherd, PC and Allan, NC and Hehlmann, R and Goldman, JM and Cross, NC and others},
  journal={Blood},
  volume={87},
  number={4},
  pages={1549--1555},
  year={1996}
}
@article{white2013establishment,
  title={Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale},
  author={White, Helen E and Hedges, John and Bendit, Israel and Branford, Susan and Colomer, Dolors and Hochhaus, Andreas and Hughes, Timothy and Kamel-Reid, Suzanne and Kim, Dong-Wook and Modur, Vijay and others},
  journal={Clinical chemistry},
  volume={59},
  number={6},
  pages={938--948},
  year={2013},
  publisher={Clinical Chemistry}
}
@article{bergstra2012random,
  title={Random search for hyper-parameter optimization},
  author={Bergstra, James and Bengio, Yoshua},
  journal={Journal of Machine Learning Research},
  volume={13},
  number={Feb},
  pages={281--305},
  year={2012}
}

@article{wazewska1976matematyczne,
  title={Matematyczne problemy dynamiki ukladu krwinek czerwonych},
  author={Wazewska-Czyzewska, M and Lasota, A},
  journal={Matematyka Stosowana VI},
  pages={23--40},
  year={1976}
}

@article{van2007oncogenic,
  title={Oncogenic signaling: new insights and controversies from chronic myeloid leukemia},
  author={Van Etten, Richard A},
  journal={Journal of Experimental Medicine},
  volume={204},
  number={3},
  pages={461--465},
  year={2007},
  publisher={Rockefeller University Press}
}

@article{van2007aberrant,
  title={Aberrant cytokine signaling in leukemia},
  author={Van Etten, Richard A},
  journal={Oncogene},
  volume={26},
  number={47},
  pages={6738},
  year={2007},
  publisher={Nature Publishing Group}
}

@article{latham2016bcr,
  title={BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia},
  author={Latham, Susan and Bartley, Paul A and Budgen, Bradley and Ross, David M and Hughes, Elizabeth and Branford, Susan and White, Deborah and Hughes, Timothy P and Morley, Alexander A},
  journal={Journal of clinical pathology},
  pages={jclinpath--2015},
  year={2016},
  publisher={BMJ Publishing Group}
}
@inproceedings{Asarin2003ReachabilityAO,
  title={Reachability Analysis of Nonlinear Systems Using Conservative Approximation},
  author={Eugene Asarin and Thao Dang and Antoine Girard},
  booktitle={HSCC},
  year={2003}
}


@article{yoshitsugu2012markov,
  title={Markov chain Monte Carlo Bayesian analysis for population pharmacokinetics of dasatinib in Japanese adult subjects with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia},
  author={YOSHITSUGU, Hiroyuki and IMAI, Yasuhiko and SERIU, Taku and HIRAOKA, Masaki},
  journal={Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics},
  volume={43},
  number={1},
  pages={29--41},
  year={2012},
  publisher={The Japanese Society of Clinical Pharmacology and Therapeutics}
}

@article{zhu2014clinical,
  title={Clinical efficacy and safety of imatinib in the management of Ph+ chronic myeloid or acute lymphoblastic leukemia in Chinese patients},
  author={Zhu, Yu and Qian, Si-Xuan},
  journal={OncoTargets and therapy},
  volume={7},
  pages={395},
  year={2014},
  publisher={Dove Press}
}

@article{hu2012mechanistic,
  title={Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase},
  author={Hu, Wenyue and Lu, Shuyan and McAlpine, Indrawan and Jamieson, Joseph D and Lee, Dong U and D. Marroquin, Lisa and Heyen, Jonathan R and Jessen, Bart A},
  journal={Toxicological Sciences},
  volume={129},
  number={1},
  pages={188--199},
  year={2012},
  publisher={Oxford University Press US}
}
@article{breccia2008differences,
  title={Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia},
  author={Breccia, Massimo and Stefanizzi, Caterina and Cannella, Laura and Latagliata, Roberto and Frustaci, Anna Maria and Carmosino, Ida and Santopietro, Michelina and Alimena, Giuliana},
  journal={Leukemia \& lymphoma},
  volume={49},
  number={12},
  pages={2328--2332},
  year={2008},
  publisher={Taylor \& Francis}
}
@article{cohen2002approval,
  title={Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia},
  author={Cohen, Martin H and Williams, Grant and Johnson, John R and Duan, John and Gobburu, Jogarao and Rahman, Atiqur and Benson, Kimberly and Leighton, John and Kim, Sung K and Wood, Rebecca and others},
  journal={Clinical Cancer Research},
  volume={8},
  number={5},
  pages={935--942},
  year={2002},
  publisher={AACR}
}
@article{jabbour2017evaluation,
  title={Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase},
  author={Jabbour, Elias J and Lin, Jay and Siegartel, Lisa R and Lingohr-Smith, Melissa and Menges, Brandy and Makenbaeva, Dinara},
  journal={Journal of medical economics},
  volume={20},
  number={9},
  pages={1007--1012},
  year={2017},
  publisher={Taylor \& Francis}
}
@article{fojo2009much,
  title={How much is life worth: cetuximab, non--small cell lung cancer, and the $440$ billion question},
  author={Fojo, Tito and Grady, Christine},
  journal={Journal of the National Cancer Institute},
  volume={101},
  number={15},
  pages={1044--1048},
  year={2009},
  publisher={Oxford University Press}
}

@article{stiehl2012mathematical,
  title={Mathematical modeling of leukemogenesis and cancer stem cell dynamics},
  author={Stiehl, Thomas and Marciniak-Czochra, Anna},
  journal={Mathematical Modelling of Natural Phenomena},
  volume={7},
  number={1},
  pages={166--202},
  year={2012},
  publisher={EDP Sciences}
}


@article{effetto-imatinib-1,
  title={CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl--positive human leukemia cells to apoptosis due to antileukemic drugs},
  author={Fang, Guofu and Kim, Caryn Naekyung and Perkins, Charles L and Ramadevi, Nimmanapalli and Winton, Elliott and Wittmann, Sylvie and Bhalla, Kapil N},
  journal={Blood},
  volume={96},
  number={6},
  pages={2246--2253},
  year={2000},
  publisher={Am Soc Hematology}
}

@article{effetto-imatinib-2,
  title={Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells},
  author={Yu, Chunrong and Krystal, Geoffrey and Dent, Paul and Grant, Steven},
  journal={Clinical Cancer Research},
  volume={8},
  number={9},
  pages={2976--2984},
  year={2002},
  publisher={AACR}
}


@article{effetto-imatinib-3,
  title={Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR--ABL tyrosine kinase},
  author={Vigneri, Paolo and Wang, Jean YJ},
  journal={Nature medicine},
  volume={7},
  number={2},
  pages={228},
  year={2001},
  publisher={Nature Publishing Group}
}
@article{miller2000haber,
  title={Haber’s rule: a special case in a family of curves relating concentration and duration of exposure to a fixed level of response for a given endpoint},
  author={Miller, Frederick J and Schlosser, Paul M and Janszen, Derek B},
  journal={Toxicology},
  volume={149},
  number={1},
  pages={21--34},
  year={2000},
  publisher={Elsevier}
}



@article{griffin1986clonogenic,
  title={Clonogenic cells in acute myeloblastic leukemia},
  author={Griffin, JD and Lowenberg, B},
  journal={Blood},
  volume={68},
  number={6},
  pages={1185--1195},
  year={1986}
}


@article{calvi2003osteoblastic,
  title={Osteoblastic cells regulate the haematopoietic stem cell niche},
  author={Calvi, LM and Adams, GB and Weibrecht, KW and Weber, JM and Olson, DP and Knight, MC and Martin, RP and Schipani, E and Divieti, P and Bringhurst, F Rv and others},
  journal={Nature},
  volume={425},
  number={6960},
  pages={841},
  year={2003},
  publisher={Nature Publishing Group}
}

@article{zhang2003identification,
  title={Identification of the haematopoietic stem cell niche and control of the niche size},
  author={Zhang, Jiwang and Niu, Chao and Ye, Ling and Huang, Haiyang and He, Xi and Tong, Wei-Gang and Ross, Jason and Haug, Jeff and Johnson, Teri and Feng, Jian Q and others},
  journal={Nature},
  volume={425},
  number={6960},
  pages={836},
  year={2003},
  publisher={Nature Publishing Group}
}

@article{garrido2001acute,
  title={Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5)},
  author={Garrido, Sara M and Appelbaum, Frederick R and Willman, Cheryl L and Banker, Deborah E},
  journal={Experimental hematology},
  volume={29},
  number={4},
  pages={448--457},
  year={2001},
  publisher={Elsevier}
}

@article{layton1989evidence,
  title={Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor},
  author={Layton, Judith E and Hockman, Helen and Sheridan, William P and Morstyn, George},
  journal={Blood},
  volume={74},
  number={4},
  pages={1303--1307},
  year={1989},
  publisher={Am Soc Hematology}
}


@article{metcalf2008hematopoietic,
  title={Hematopoietic cytokines},
  author={Metcalf, Donald},
  journal={Blood},
  volume={111},
  number={2},
  pages={485--491},
  year={2008},
  publisher={Am Soc Hematology}
}

@article{fried2009erythropoietin,
  title={Erythropoietin and erythropoiesis},
  author={Fried, Walter},
  journal={Experimental hematology},
  volume={37},
  number={9},
  pages={1007--1015},
  year={2009},
  publisher={Elsevier}
}

@incollection{marciniak2013mathematical,
  title={Mathematical models of hematopoietic reconstitution after stem cell transplantation},
  author={Marciniak-Czochra, Anna and Stiehl, Thomas},
  booktitle={Model Based Parameter Estimation},
  pages={191--206},
  year={2013},
  publisher={Springer}
}


@article{himmelstein2009medical,
  title={Medical bankruptcy in the United States, 2007: results of a national study},
  author={Himmelstein, David U and Thorne, Deborah and Warren, Elizabeth and Woolhandler, Steffie},
  journal={The American journal of medicine},
  volume={122},
  number={8},
  pages={741--746},
  year={2009},
  publisher={Elsevier}
}



@misc{chen2017journey,
  title={Journey of generic imatinib: a case study in oncology drug pricing},
  author={Chen, Christopher T and Kesselheim, Aaron S},
  year={2017},
  publisher={American Society of Clinical Oncology}
}
@article{mughal2010principal,
  title={Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase},
  author={Mughal, Tariq I and Schrieber, Andrew},
  journal={Biologics: targets \& therapy},
  volume={4},
  pages={315},
  year={2010},
  publisher={Dove Press}
}
@article{zhang2010effective,
  title={Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate},
  author={Zhang, Bin and Strauss, Adam C and Chu, Su and Li, Min and Ho, Yinwei and Shiang, Keh-Dong and Snyder, David S and Huettner, Claudia S and Shultz, Leonard and Holyoake, Tessa and others},
  journal={Cancer cell},
  volume={17},
  number={5},
  pages={427--442},
  year={2010},
  publisher={Elsevier}
}
@article{zhou2015leukemia,
  title={Leukemia stem cells: the root of chronic myeloid leukemia},
  author={Zhou, Hong and Xu, Rongzhen},
  journal={Protein \& cell},
  volume={6},
  number={6},
  pages={403--412},
  year={2015},
  publisher={Springer}
}
@article{graham2002primitive,
  title={Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro},
  author={Graham, Susan M and J{\o}rgensen, Heather G and Allan, Elaine and Pearson, Charlie and Alcorn, Michael J and Richmond, Linda and Holyoake, Tessa L},
  journal={Blood},
  volume={99},
  number={1},
  pages={319--325},
  year={2002},
  publisher={Am Soc Hematology}
}


@article{bruns2009hematopoietic,
  title={The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence},
  author={Bruns, I and Czibere, A and Fischer, JC and Roels, F and Cadeddu, RP and Buest, S and Bruennert, D and Huenerlituerkoglu, AN and Stoecklein, NH and Singh, R and others},
  journal={Leukemia},
  volume={23},
  number={5},
  pages={892},
  year={2009},
  publisher={Nature Publishing Group}
}
@article{till1964stochastic,
  title={A stochastic model of stem cell proliferation, based on the growth of spleen colony-forming cells},
  author={Till, James E and McCulloch, Ernest A and Siminovitch, Louis},
  journal={Proceedings of the National Academy of Sciences},
  volume={51},
  number={1},
  pages={29--36},
  year={1964},
  publisher={National Acad Sciences}
}

@article{tomasetti2010role,
  title={Role of symmetric and asymmetric division of stem cells in developing drug resistance},
  author={Tomasetti, Cristian and Levy, Doron},
  journal={Proceedings of the National Academy of Sciences},
  volume={107},
  number={39},
  pages={16766--16771},
  year={2010},
  publisher={National Acad Sciences}
}
@article{pk-imatinib-1,
  title={Clinical pharmacokinetics of imatinib mesylate},
  author={Leveque, Dominique and Maloisel, Fr{\'e}d{\'e}ric},
  journal={in vivo},
  volume={19},
  number={1},
  pages={77--84},
  year={2005},
  publisher={International Institute of Anticancer Research}
}
@article{pk-imatinib-2,
  title={Clinical pharmacokinetics of imatinib},
  author={Peng, Bin and Lloyd, Peter and Schran, Horst},
  journal={Clinical pharmacokinetics},
  volume={44},
  number={9},
  pages={879--894},
  year={2005},
  publisher={Springer}
}
@article{pk-imatinib-3,
  title={Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study},
  author={Larson, Richard A and Druker, Brian J and Guilhot, Francois and O'Brien, Stephen G and Riviere, Gilles J and Krahnke, Tillmann and Gathmann, Insa and Wang, Yanfeng},
  journal={Blood},
  volume={111},
  number={8},
  pages={4022--4028},
  year={2008},
  publisher={Am Soc Hematology}
}

@article{druker1996effects,
  title={Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr--Abl positive cells},
  author={Druker, Brian J and Tamura, Shu and Buchdunger, Elisabeth and Ohno, Sayuri and Segal, Gerald M and Fanning, Shane and Zimmermann, J{\"u}rg and Lydon, Nicholas B},
  journal={Nature medicine},
  volume={2},
  number={5},
  pages={561},
  year={1996},
  publisher={Nature Publishing Group}
}
@article{buchdunger1996inhibition,
  title={Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative},
  author={Buchdunger, Elisabeth and Zimmermann, J{\"u}rg and Mett, Helmut and Meyer, Thomas and M{\"u}ller, Marcel and Druker, Brian J and Lydon, Nicholas B},
  journal={Cancer research},
  volume={56},
  number={1},
  pages={100--104},
  year={1996},
  publisher={AACR}
}


